Optimized patient transfer using an innovative multidisciplinary assessment in the Kanton Aargau (OPTIMA I): an observational survey in lower respiratory tract infections

[1]  T. Bregenzer,et al.  Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: Derivation of a clinical algorithm , 2011, BMC infectious diseases.

[2]  D. Moertl,et al.  Cost analysis and cost‐effectiveness of NT‐proBNP‐guided heart failure specialist care in addition to home‐based nurse care , 2011, European journal of clinical investigation.

[3]  M. Christ-Crain,et al.  Prognostic value of procalcitonin in community-acquired pneumonia , 2010, European Respiratory Journal.

[4]  N. Morgenthaler,et al.  Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections , 2010, Critical care.

[5]  S. De Geest,et al.  Which patients with lower respiratory tract infections need inpatient treatment? Perceptions of physicians, nurses, patients and relatives , 2010, BMC pulmonary medicine.

[6]  S. Willich,et al.  [Is the determination of biomarkers worth its price? Review of the literature taking brain natriuretic peptides (BNP) as an example]. , 2010, Herz.

[7]  M. Fine,et al.  Reasons why emergency department providers do not rely on the pneumonia severity index to determine the initial site of treatment for patients with pneumonia. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  T. Bregenzer,et al.  Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. , 2009, JAMA.

[9]  Nathan A. Pugh,et al.  Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. , 2009, Chest.

[10]  Mirjam Christ-Crain,et al.  Prognostic impact of plasma lipids in patients with lower respiratory tract infections - an observational study. , 2009, Swiss medical weekly.

[11]  M. Briel,et al.  Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. , 2008, Archives of internal medicine.

[12]  T. Perneger,et al.  A predictive score to identify hospitalized patients' risk of discharge to a post-acute care facility , 2008, BMC health services research.

[13]  J. Struck,et al.  Endothelin-1 precursor peptides correlate with severity of disease and outcome in patients with community acquired pneumonia , 2008, BMC infectious diseases.

[14]  A. Grossman,et al.  Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. , 2007, American journal of respiratory and critical care medicine.

[15]  R. Wolfe,et al.  Effect of 10 days of bed rest on skeletal muscle in healthy older adults. , 2007, JAMA.

[16]  J. Bartlett,et al.  Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  T. Marrie,et al.  Admission is not always necessary for patients with community-acquired pneumonia in risk classes IV and V diagnosed in the emergency room. , 2007, Canadian respiratory journal.

[18]  M. Christ-Crain,et al.  Diagnostic value of signs, symptoms and laboratory values in lower respiratory tract infection. , 2006, Swiss medical weekly.

[19]  M. Fine,et al.  Factors associated with the hospitalization of low-risk patients with community-acquired pneumonia in a cluster-randomized trial , 2006, Journal of General Internal Medicine.

[20]  J. Struck,et al.  Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397] , 2006, Critical care.

[21]  Ron Goeree,et al.  Effect of a clinical pathway to reduce hospitalizations in nursing home residents with pneumonia: a randomized controlled trial. , 2006, JAMA.

[22]  C. Schindler,et al.  Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. , 2006, Archives of internal medicine.

[23]  J. Struck,et al.  Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. , 2005, Clinical chemistry.

[24]  T. Marrie,et al.  Factors Influencing In-hospital Mortality in Community-Acquired Pneumonia , 2005, Chest.

[25]  J. Dorca,et al.  Outpatient Care Compared with Hospitalization for Community-Acquired Pneumonia , 2005, Annals of Internal Medicine.

[26]  L. Mandell.  Decisions about Treating Community-Acquired Pneumonia , 2005, Annals of Internal Medicine.

[27]  J. McMurray,et al.  The clinical relevance of adrenomedullin: a promising profile? , 2004, Pharmacology & therapeutics.

[28]  T. Welte,et al.  CAPNETZ—Community-Acquired Pneumonia Competence Network , 2004, Infection.

[29]  H. Pratt,et al.  Validation of short screening tests for depression and cognitive impairment in older medically ill inpatients , 2004, International journal of geriatric psychiatry.

[30]  J. White,et al.  Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. , 2004, The Journal of clinical endocrinology and metabolism.

[31]  M. Aliyu,et al.  Determinants for hospitalization in " low-risk" community acquired pneumonia , 2003, BMC infectious diseases.

[32]  W. Lim,et al.  Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study , 2003, Thorax.

[33]  Gilles Clermont,et al.  Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. , 2002, American journal of respiratory and critical care medicine.

[34]  M. Fine,et al.  Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. , 2001, American journal of respiratory and critical care medicine.

[35]  R. Gonzales,et al.  Uncomplicated Acute Bronchitis , 2000, Annals of Internal Medicine.

[36]  T. Marrie.  Community-acquired pneumonia in the elderly. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  M. Tinetti,et al.  Older person's preferences for home vs hospital care in the treatment of acute illness. , 2000, Archives of internal medicine.

[38]  I. Bolíbar,et al.  Epidemiology of community-acquired pneumonia in adults: a population-based study. , 2000, The European respiratory journal.

[39]  L. Mandell,et al.  Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. , 2000, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.

[40]  T. Marrie.  Risks and outcomes in community acquired pneumonia. , 1999, Canadian respiratory journal.

[41]  M. Niederman,et al.  The cost of treating community-acquired pneumonia. , 1998, Clinical therapeutics.

[42]  D. Singer,et al.  Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. , 1998, Archives of internal medicine.

[43]  M. Fine,et al.  A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.

[44]  A. Detsky,et al.  Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia. , 1996, Archives of internal medicine.